ZVRA Stock Forecast & Price Target

Zevra Therapeutics Inc. has demonstrated strong market traction following the launch of its therapy MIPLYFFA, reflected by $10.1 million in sales during the first quarter, significantly surpassing initial estimates. The company exhibits a robust growth trajectory with an increasing number of patient enrollments—109 TRx forms received as of December 31, 2024—indicative of strong demand and effective outreach strategies. Additionally, as awareness campaigns develop and the company expands its market reach, particularly in the European market with an estimated 1,100 Niemann-Pick type C patients, the outlook for 2025 sales remains highly optimistic.

Zevra Therapeutics is facing significant financial challenges, as reflected by a GAAP net income loss of $20.4 million and a substantial 4Q net loss of $35.7 million, indicating ongoing struggles for profitability. Compounding these issues are concerns regarding poor payer coverage and recent competitor approvals, which could negatively impact drug sales and market penetration for their offerings, including Miplyffa and Olpruva. Additionally, the company's pipeline holds risks of failure in clinical stages, limiting future development options and further depressing investor interest amidst a history of sustained losses.